ALK and non-small cell lung carcinoma: In the ongoing phase I dose expansion study (NCT03260491), the cohort of patients with advanced NSCLC without EGFR mutation who received prior platinum-based chemotherapy with or without immune therapy showed promising clinical activity, including patients with other driver genomic alterations, such as KRAS, NRAS, ALK and ROS142.